España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Urologix
ULGX
OTCEM
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.00010
At close: Dec 20, 3:47 PM EDT
Get Report
Comment
Urologix (ULGX) Forecast
News
Earnings
Urologix (ULGX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Urologix (OTC:ULGX) Stock
Urologix Stock (OTC: ULGX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, March 24, 2020
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
Tuesday, February 25, 2020
Stocks That Hit 52-Week Lows On Tuesday
Lisa Levin
Tuesday, November 26, 2019
Stocks That Hit 52-Week Lows On Tuesday
Lisa Levin
Tuesday, August 19, 2014
8-K from Urologix Shows CFO Brian Smrdel Resi...
Benzinga
Urologix, Inc. Reports Q4 EPS of $(0.17), Down 113% YOY; Revenue of $3.30M, Down 27% YOY
Benzinga
Tuesday, May 06, 2014
Urologix, Inc. Reports Q3 EPS of $(0.08), Unchanged YOY; Revenue of $3.40M, Down 24% YOY
Benzinga
Thursday, April 10, 2014
Urologix, Inc. Reports Prelim. Q3 Sales $3.40M
Benzinga
Tuesday, February 04, 2014
Urologix, Inc. Reports Q2 EPS of $(0.05), Up 38% YOY; Revenue of $3.81M, Down 15% YOY
Benzinga
Tuesday, August 20, 2013
Urologix, Inc. Sees FY2014 Sales $15.0M-17.0M
Benzinga
Urologix, Inc. Reports Q2 EPS of $(0.06), Up 25% YOY; Revenue of $4.18M vs $3.77M Est
Benzinga
Friday, June 14, 2013
Can Companies Recover from a Nasdaq or NYSE Delisting?
Benzinga
Wednesday, May 01, 2013
Urologix, Inc. Sees FY2013 Sales $16.0M-17.0M; Reaffirms Outlook
Benzinga
Urologix, Inc. Reports Q3 EPS of $(0.05) vs $(0.06) Est; Revenue of $4.08M vs $3.85M Est
Benzinga
Wednesday, April 17, 2013
Urologix Receives Extension from NASDAQ to Re...
Benzinga
Monday, April 08, 2013
Urologix Reports Important Milestone in Prostiva(R) RF Therapy Licensing Deal
Benzinga
Wednesday, January 30, 2013
Urologix Names Greg Fluet CEO
Benzinga
Thursday, August 23, 2012
Urologix Reports Q4 EPS $-0.08; Revenues $4.5M
Benzinga
Tuesday, July 17, 2012
Dougherty & Company Initiates Coverage on Uro...
Benzinga
Friday, June 29, 2012
Urologix Announces Pricing of Follow-On Offering of 5.2M Shares of Common Stock at $0.75
Benzinga
Friday, June 08, 2012
Urologix Amends Filing, Offering 5.2M Shares
Benzinga
Wednesday, June 06, 2012
Morning Market Losers
Benzinga
Tuesday, January 24, 2012
Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter
Benzinga
Thursday, January 12, 2012
Urologix Secures $2 Million Credit Facility
Benzinga
Friday, January 06, 2012
Urologix Regains Nasdaq Minimum Bid Price Requirement
Benzinga
Tuesday, September 06, 2011
MAKO Surgical and Urologix Hit New 52-Week Highs
Benzinga
Urologix Announces Signing of an Exclusive Worldwide License for the Prostiva RF Therapy System for BPH
Benzinga
Thursday, June 30, 2011
Urologix Regains Compliance with NASDAQ Minim...
Benzinga
Tuesday, December 29, 2009
New 52-Week High Stocks (ULGX, MSFT, OSIS, ANX)
Benzinga
